Alzheimer’s disease doesn’t have a single cause. It develops from a combination of genetic, biological, and lifestyle factors that interact over decades. While researchers continue to refine the picture, three major drivers consistently emerge: inherited genetic risk, the buildup of toxic proteins in the brain, and chronic inflammation fueled by vascular and metabolic problems. An estimated 7.4 million Americans age 65 and older are living with Alzheimer’s, and understanding what causes it starts with these three interconnected pathways.
1. Genetics and Inherited Risk
Your genes play a significant role in determining whether you develop Alzheimer’s, though the type of genetic risk varies dramatically depending on when the disease appears.
Early-Onset Alzheimer’s
A small percentage of Alzheimer’s cases strike before age 65, and these are often driven by rare mutations in one of three specific genes: APP on chromosome 21, PSEN1 on chromosome 14, and PSEN2 on chromosome 1. These aren’t risk factors in the usual sense. If you inherit one of these variants from a parent, you have a very strong probability of developing the disease, sometimes well before 65. A child of a carrier has a 50/50 chance of inheriting the mutation. These cases account for a tiny fraction of all Alzheimer’s, but they’ve been invaluable for understanding how the disease works at a molecular level.
Late-Onset Alzheimer’s
The vast majority of cases appear after 65, and here the genetic picture is murkier. The most well-known genetic risk factor is a variant of the APOE gene called APOE ε4. About 15% to 25% of people carry one copy of this variant, and 2% to 5% carry two copies. Having two copies is associated with substantially higher risk than having one. But carrying APOE ε4 doesn’t guarantee you’ll develop Alzheimer’s, and plenty of people without it do. It shifts the odds and tends to push the age of onset earlier, but it’s one piece of a larger puzzle involving dozens of other genes, each contributing a small amount of risk.
2. Toxic Protein Buildup in the Brain
The hallmark of Alzheimer’s is the accumulation of two abnormal proteins in brain tissue: amyloid-beta plaques and tau tangles. These aren’t just markers of the disease. They actively destroy neurons and the connections between them.
Amyloid-beta starts causing trouble before plaques even form. Small, soluble clusters of the protein (called oligomers) collect at the junctions where brain cells communicate. These oligomers are abundant in the synapses of Alzheimer’s patients early in the disease, disrupting signaling between neurons and contributing to the earliest symptoms of memory loss and confusion. Over time, the protein clumps into the larger plaques visible on brain scans, which cause further neuronal death and tissue damage.
Tau protein normally helps maintain the internal scaffolding that neurons need to transport nutrients and signals along their length. In Alzheimer’s, tau becomes chemically altered and detaches from this scaffolding, forming tangled threads inside neurons. These tangles collapse the cell’s transport system, starving it of what it needs to function. What makes tau especially dangerous is its ability to spread. Once misfolded tau enters a neighboring cell, it can escape its compartment and serve as a template, forcing normal tau to misfold as well. This chain reaction propagates through connected brain networks, which is why Alzheimer’s symptoms worsen in a somewhat predictable pattern over time.
Research suggests amyloid-beta accumulation comes first and may trigger the tau cascade. Soluble amyloid oligomers appear in synapses before phosphorylated tau shows up at later stages, pointing to amyloid as the initial spark that drives tau accumulation and its spread across the brain. This sequence is the basis for newer treatments that target amyloid removal. The FDA has approved antibody therapies that reduce amyloid levels measured by brain imaging, with treatment adjusted based on how much plaque has been cleared at specific intervals.
3. Chronic Inflammation and Vascular Damage
The brain has its own immune system, and when it goes into overdrive, it becomes a third major driver of Alzheimer’s. The key players are microglia, immune cells that act as the brain’s cleanup crew. Under normal conditions, microglia clear debris and even help remove amyloid-beta. But when they become chronically activated, they switch from protective to destructive.
Long-term activation of microglia triggers a self-reinforcing cycle of inflammation. The activated cells release inflammatory molecules that damage neurons and strip away synapses. They also lose their ability to clear amyloid-beta efficiently, which means more protein accumulates, which triggers more inflammation. Brain scans of Alzheimer’s patients show that microglial activation correlates with reduced glucose metabolism in the brain, a sign that synapses are failing. The inflammatory signals also reprogram other support cells in the brain, causing them to stop nourishing neurons and instead release toxic compounds.
What kicks microglia into this harmful state? The list is long: brain trauma, systemic inflammation from conditions elsewhere in the body, obesity, and physical inactivity all contribute. This is where vascular and metabolic health enters the picture. Diabetes, high blood pressure, obesity, and high LDL cholesterol all increase Alzheimer’s risk through overlapping mechanisms involving inflammation, oxidative stress, and damage to the blood-brain barrier (the protective layer that controls what enters brain tissue from the bloodstream). When this barrier breaks down, harmful substances reach the brain more easily and amplify the inflammatory cycle.
How These Three Causes Interact
These three drivers don’t operate in isolation. Genetic risk can accelerate protein buildup. Protein buildup triggers inflammation. Inflammation worsens protein accumulation. Vascular damage compromises the brain’s ability to clear toxic proteins. This is why Alzheimer’s is so difficult to prevent or treat with a single approach, and why the updated 2024 diagnostic criteria from the National Institute on Aging now define the disease by its underlying biology rather than symptoms alone, incorporating amyloid, tau, neurodegeneration, inflammation, and vascular injury into a single diagnostic framework.
The Role of Modifiable Risk Factors
While you can’t change your genes, a striking amount of Alzheimer’s risk is tied to factors you can influence. The 2024 Lancet Commission report estimates that addressing 14 modifiable risk factors could prevent or delay nearly half of all dementia cases. The factors linked to the greatest proportion of cases globally are hearing impairment and high LDL cholesterol (7% of cases each), followed by less education in early life and social isolation in later life (5% each).
The full list spans a lifetime: lower levels of education in childhood, hearing loss, high blood pressure, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, social isolation, high LDL cholesterol starting around age 40, and untreated vision loss in later life. Each of these connects back to one or more of the three core causes. High blood pressure and cholesterol damage blood vessels and the blood-brain barrier. Physical inactivity and obesity promote chronic inflammation. Traumatic brain injury activates microglia. The takeaway is that while Alzheimer’s has deep biological roots, the soil those roots grow in is shaped by choices and conditions that accumulate across decades.